News articles about OvaScience (NASDAQ:OVAS) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OvaScience earned a news impact score of 0.21 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.1257069601933 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of OvaScience (OVAS) remained flat at $$1.39 during trading hours on Tuesday. The company’s stock had a trading volume of 234,500 shares, compared to its average volume of 570,605. OvaScience has a twelve month low of $1.25 and a twelve month high of $4.20.
OVAS has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of OvaScience from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a report on Wednesday, October 4th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of OvaScience in a report on Thursday, August 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of OvaScience in a report on Monday, November 6th.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://sportsperspectives.com/2017/11/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-ovascience-ovas-stock-price.html.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.